NRG-HN003: Phase I and Expansion Cohort Study of Adjuvant Pembrolizumab, Cisplatin and Radiation Therapy in Pathologically High-Risk Head and Neck Cancer

SIMPLE SUMMARY: The anti-PD1 monoclonal antibody pembrolizumab improves survival in recurrent/metastatic head and neck squamous cell carcinoma. Patients with locoregional, pathologically high-risk disease recur frequently despite adjuvant cisplatin–radiation therapy. Targeting PD1 may reverse immuno...

Descripción completa

Detalles Bibliográficos
Autores principales: Bauman, Julie E., Harris, Jonathan, Uppaluri, Ravindra, Yao, Min, Ferris, Robert L., Chen, Josephine, Jordan, Richard C., Joshi, Nikhil P., Jujjuvaparu, Srinivas, Blakaj, Dukagjin M., Henson, Christina, Sheqwara, Jawad, Mell, Loren K., Sen, Neilayan, Clump, David A., Garg, Madhur K., Yilmaz, Emrullah, Torres-Saavedra, Pedro, Le, Quynh-Thu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8230356/
https://www.ncbi.nlm.nih.gov/pubmed/34207599
http://dx.doi.org/10.3390/cancers13122882

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8230356/
https://www.ncbi.nlm.nih.gov/pubmed/34207599
http://dx.doi.org/10.3390/cancers13122882

Ejemplares similares